Koers Compugen Ltd. TEL AVIV STOCK EXCHANGE
Aandelen
IL0010852080
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 37,9 mln. 14,43 mld. 35,45 mln. | Omzet 2025 * | 35,29 mln. 13,43 mld. 33 mln. | Marktkapitalisatie | 172 mln. 65,44 mld. 161 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -13 mln. -4,95 mld. -12,16 mln. | Nettowinst (verlies) 2025 * | -29 mln. -11,04 mld. -27,12 mln. | EV/omzet 2024 * | 4,54 x |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | 4,87 x |
K/w-verhouding 2024 * |
-14,8
x | K/w-verhouding 2025 * |
-7,11
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 94,62% |
Recentste transcriptie over Compugen Ltd.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Anat Cohen-Dayag
CEO | Chief Executive Officer | 57 | 01-01-02 |
Alberto Sessa
DFI | Director of Finance/CFO | 61 | 01-11-22 |
Eran Ophir
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-15 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Paul Sekhri
CHM | Chairman | 66 | 02-10-17 |
Sanford Zweifach
BRD | Director/Board Member | 68 | 11-06-18 |
Gilead Halevy
BRD | Director/Board Member | 57 | 11-06-18 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+1,51% | 42,75 mld. | |
+49,22% | 41,61 mld. | |
+8,57% | 41,34 mld. | |
-12,36% | 26,59 mld. | |
+8,92% | 25,49 mld. | |
-25,13% | 18,12 mld. | |
+29,17% | 12,24 mld. | |
-3,12% | 11,76 mld. | |
+6,35% | 11 mld. |